期刊文献+

药物性低镁血症27例临床分析 被引量:1

原文传递
导出
摘要 目的探讨在普通人群中药物性低镁血症的特点及规律,为临床早期诊断和治疗提供依据。方法回顾分析2009年1月1日至2011年1月1日期间收治的27例药物性低镁血症患者的临床资料。结果本组27例药物性低镁血症中,女性15例,男性12例(1.25:1);年龄16~76岁。致病药物中利尿药物居首位,其次分别为抗病毒类药物、抗肿瘤类药物、免疫抑制剂及抗寄生虫类药物等。结论对临床药物所致低镁血症,首要应以预防为主,一旦确诊,应及时补充镁盐,但完全补足体内缺镁需时较长,需解除症状后持续补镁1~3周。
作者 张旭 吴歌
出处 《中国临床研究》 CAS 2011年第10期942-942,968,共2页 Chinese Journal of Clinical Research
  • 相关文献

参考文献5

  • 1徐静,陈楠.低血镁与糖代谢异常[J].中国实用内科杂志,2007,27(24):1971-1973. 被引量:12
  • 2Kuipers MT, Thang HD, Amtzenius AB. Hypomagnesaemia due to use of proton pump inhibitors--a review[ J ]. Neth J Med, 2009,67 (5) :169 - 172.
  • 3Tomar M, Radhakrishnan S, Shrivastava S. Myocardial dysfunction due to hypocalcemia[J]. Indian Pediatr,2010,47 (9) :781 - 783.
  • 4Ayad RF, Assar MD, Simpson L, et al. Causes and management of drug-induced long QT syndrome[ J]. Proc ( Bayl Univ Med Cent), 2010,23 (3) :250 - 255.
  • 5徐亮.药物引起的低镁血症[J].国外医学(药学分册),2006,33(5):374-376. 被引量:4

二级参考文献24

  • 1Flatman PW. Magnesium transport across cell membrane [ J ]. Membrane Bio,1984,180( 1 ) :1 -4.
  • 2Lostroh A J, Krahl ME. Accumulation in vitro of magnesium and potassium in rat uterus ion pump activity[ J ]. Bioch Bioph Acta, 1973,291:260 -268.
  • 3Paolisso G, Sgambato S, Passariello B, et al. Insulin induces opposite changes in plasma and erythrocyte magnesium concentrations in normal man [ J ]. Diabetologia, 1986,29 ( 9 ) :644 - 647.
  • 4Reinhart RA. Magnesium metabolism:a review with special reference to the relationship between intracellular content and serum levels [ J ]. Arch Intern Med, 1988,148 ( 11 ) :2415 - 2420.
  • 5Paolisso G, Passariello N, Sgambato S, et al. Impaired insulin-mediated erythrocyte magnesium accumulation in essential hypertension[J]. Clin Sci ,1987,73(5) :535 -539.
  • 6Rosolova H, Mayer O Jr, Reaven GM. Insulin-mediated glucose disposal is decreased in normal subjects with relatively low plasma magnesium concentrations [ J ]. Metabolism, 2000,49 ( 3 ) : 418 - 420.
  • 7Koherman OG, Gray RS, Griffin J, et al. Receptor and postreceptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus [ J ]. J Clin Invest, 1981,68 (4) :957 - 969.
  • 8Takaya J, Higashino H, Kobayashi Y. Intracellular magnesium and insulin resistance [ J ]. Magnes Res,2004,17 ( 2 ) : 126 - 136.
  • 9Barbagallo M, Dominguez LJ, Resnick LM. Insulin-mimetic action of vanadate: role of intracellular magnesium [ J ]. Hypertension, 2001,38(3 Pt 2) :701 -704.
  • 10Longstreet DA,Heath DL,Vink R. A potential link between magnesium intake and diabetes in Indigenous Australians[ J]. Med J Aust,2005,183 (4) :219 - 220.

共引文献14

同被引文献8

  • 1王鸿利.实验诊断学[M].2版.北京:人民卫生出版社,2006: 246.
  • 2U. S. Department Of Health And Human Services,National Institutesof Health, National Cancer Institute. Common TerminologyCriteria for Adverse Events ( CTCAE ) Version 4. 0[ EB/OL].(2009-05-28 ) [ 2014-01-10 ]. http://evs. nci. nih. gov/ftpl/CTCAE/CTCAE_4. 03_2010-06-14_QuickReference_5x7. pdf.
  • 3Jonker DJ, 0Callaghan CJ, Karapetis CS, et al. Cetuximab forthe treatment of colorectal cancer[ J]. N Engl J Med, 2007 , 357(20) ; 2040-2048.
  • 4Schrag D, Chung KY, Flombaum C, et al. Cetuximab therapy andsymptomatic hypomagnesemia[ J]. J Natl Cancer Inst, 2005 , 97(16): 1221-1224.
  • 5Fakih MG, Wilding G, Lombardo J. Cetuximab-induced hypomag-nesemia in patients with colorectal cancer [ J ]. Clin ColorectalCancer. 2006, 6(2) ; 152-156.
  • 6Chen P, Wang L, Li H, et al. Incidence and risk of hypomag-nesemia in advanced cancer patients treated with cetuximab: ameta-analysis[ J]. Oncol Lett, 2013,5(6) : 1915-1920.
  • 7Tejpar S, Piessevaux H,Claes K, et al. Magnesium wasting asso-ciated with epidermal-growth-factor receptor-targeting antibodies incolorectal cancer: a prospective study[ J]. Lancet Oncol,2007,8(5): 387-394.
  • 8李洪涛,刘宏斌,赵青川,韩晓鹏,朱万坤,苏琳.EGFR靶向药物西妥昔单抗在结直肠癌治疗中的应用进展[J].中华消化外科杂志,2013,12(7):556-560. 被引量:8

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部